News

Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint ...
STAT6d
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit ...
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
KEY TAKEAWAYS French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday ...
pharmaphorum6h
Kymera signs $750m cancer deal with Gilead as Sanofi opts in
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...
KTLA23d
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - KTLA
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
The Victoria Advocate13d
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib ... - Victoria Advocate
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in ...
Fintel on MSN22d
Stephens & Co. Downgrades Blueprint Medicines (BPMC)
Fintel reports that on June 3, 2025, Stephens & Co. downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 0.09% Downside As ...
GEN23d
Sanofi to Acquire Blueprint Medicines for Up to $9.5B
Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...
Wall Street Journal23d
Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline - WSJ - The Wall Street Journal
Sanofi SAN-0.71%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC-0.05%decrease; red down pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...
Morningstar23d
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - Morningstar
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
The Victoria Advocate23d
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...